课题基金 / 基金详情

COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS & PROTEINS

COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS & PROTEINS
COBRE:UK KS:P1:HSP90 辅助伴侣、免疫亲和素的 ID
批准号:
7720669
负责人:
Brian S J Blagg
金额:
$2.61万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-05-15 至 2009-03-31

项目摘要

项目成果

Brian S J Blagg的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hsp90 molecular chaperones are responsible for the conformational maturation of linear peptides into active three-dimensional enzymes and receptors. Examples of proteins dependent on the Hsp90 protein folding machinery include steroid hormone receptors, Src kinase, Her-2 kinase, Raf, p185, mutant p53, telomerase, PKR, telomerase, nitric oxide synthase, CDK-4 and CDK-6 to name a few. As Hsp90 continues to evolve into a popular target for the treatment of cancer more information is required to validate its role in the maturation of key regulatory proteins. For example, it is not known how many client proteins require Hsp90 for folding, or which of the four known forms of Hsp90 (a, b, GRP94, or TRP), immunophilin (FKBP51, FKBP52, or Cyp40), or cochaperone participate in the folding of various individual client proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering the Next Generation of Safer Hsp90 Inhibitors
  • 批准号:
    10587304
  • 项目类别:
  • 资助金额:
    $46.33万
  • 财政年份:
    2023
  • 负责人:
    Brian S J Blagg
  • 依托单位:
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors
  • 批准号:
    9514012
  • 项目类别:
  • 资助金额:
    $35.33万
  • 财政年份:
    2018
  • 负责人:
    Brian S J Blagg
  • 依托单位:
Hsp90B in Bladder Cancer
  • 批准号:
    9922232
  • 项目类别:
  • 资助金额:
    $35.17万
  • 财政年份:
    2018
  • 负责人:
    Brian S J Blagg
  • 依托单位:
Optimization and Investigation of Cruentaren A analogs
  • 批准号:
    9454428
  • 项目类别:
  • 资助金额:
    $34.25万
  • 财政年份:
    2018
  • 负责人:
    Brian S J Blagg
  • 依托单位:
海外基金